Core Viewpoint - TheraVectys SA, a French biotech company, is considering an IPO in Hong Kong, potentially raising several hundred million dollars, with plans to proceed as early as this year [1] Company Overview - TheraVectys is an immunotherapy company primarily operating in France and the United States, focusing on the development of lentiviral vectors for the prevention and treatment of cancer and other diseases [1] - The company was spun off from the Pasteur Institute and has backing from Tethys Invest SAS [1] Industry Context - Foreign biotech companies typically opt for listings in Europe or the United States, making a Hong Kong IPO a rare move for non-Chinese biotech firms [1] - China is challenging Western dominance in medical innovation, reshaping the biotech industry landscape [1] - In the previous year, healthcare companies raised approximately $13 billion in the Hong Kong stock market [1]
新股消息 | 传法国生物科技公司TheraVectys拟赴港上市 或集资数亿美元
智通财经网·2026-01-06 05:49